Altium and AWS Collaborate to Advance Electronic Design
17.3.2021 11:30:00 EET | Business Wire | Press release
Altium LLC is committed to bringing transformation to the electronics industry through a digital platform that connects design to the supply chain and the manufacturing floor. To achieve this goal, Altium selected Amazon Web Services (AWS) to host Altium 365, the cloud platform for collaborative PCB design and realization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005247/en/
Altium selected Amazon Web Services (AWS) to host Altium 365, the first cloud-based platform to streamline the development and realization of printed circuit boards (PCBs). Teams can organize designs, libraries and participants in one place, and share links to their designs for easy, real-time collaboration. Designs are accessible at any time, on any device, anywhere, thanks to AWS's proven global infrastructure. (Graphic: Altium LLC)
The Altium 365 cloud-based platform and Altium Designer elevates PCB design by creating seamless collaboration points across the development process, making it the most connected design experience in the industry. This streamlines the product development process and allows engineers and designers to create smart and connected electronic products faster than ever before.
With Altium 365, users can bring together the stakeholders and participants in the electronic design process—even if they do not have Altium Designer—while keeping IPs secure and designs under control. Altium 365 provides a completely new way to share, visualize, and mark-up PCB designs for all stakeholders involved, from design managers to manufacturers, while allowing other designers to connect to the same PCB design with Altium Designer to author changes.
“AWS is central to Altium 365’s success to keep the platform, customers’ designs, and data secure, available and accessible,” said Greg Bellasis, Altium’s Director of Cybersecurity. “A broad portfolio of AWS services and the collaboration with their enterprise support team helps us achieve this goal to ensure ongoing stability, security, and reliability for our users to connect with anyone, from anywhere, in any time zone and from any web-enabled device to get their job done.”
Teams can organize designs, libraries, and participants in one place, and share links to their designs for easy, real-time collaboration. Designs are accessible at any time, on any device, anywhere, thanks to AWS’s proven global infrastructure. By leveraging CAD-specific intelligence, design data can be stored in a way that makes projects, files and version history accessible and easy to navigate on the web.
As Michael Weston, Lead Engineer in Kinetic Vision’s Product Design and Development Group, explains, “We switched over to Altium 365 in January 2020 because we needed a more stable platform for our data and collaboration methods compared to the local methods we were using, but with the COVID-19 situation, the platform became even more essential because our team members could continue to work remotely. Altium 365 has given us more power to create brilliant work—no matter where our team is working from.”
“There’s a broad recognition that cloud is a more secure place to do collaborative projects than traditional on-premises infrastructures,” said David Pellerin, head of Worldwide Business Development for Infotech/Semiconductor at AWS. “By using the cloud to secure their most sensitive data and improve efficiencies and maximize collaboration, Altium and their customers can free up developers and engineers to focus on innovation.”
By combining the flexibility of sharing and collaboration in the cloud with the power of desktop PCB design software, Altium is making a big leap towards modernizing and transforming the way the electronics industry meets the growing demand for smart and connected products.
ABOUT ALTIUM
Altium LLC, a global software company headquartered in San Diego, California, is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005247/en/
Contact information
Masha V. Petrova
VP, Brand and Communications
pr@altium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
